Biologics and chronic obstructive pulmonary diseases

Biologics and chronic obstructive pulmonary diseases

The presence of airway inflammation in patients with chronic obstructive pulmonary disease (COPD) provides a rationale for biological agents targeting specific inflammatory pathways. This approach has been strikingly effective in patients with other chronic inflammatory diseases, such as rheumatoid...

Bibliografski detalji
Glavni autor:	Pavord, I
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2018

Slični predmeti

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
od: Pavord, I
Izdano: (2018)

Chronic obstructive pulmonary disease in non-smokers.
od: Pavord, I, i dr.
Izdano: (2009)

Asthma-like features and chronic obstructive pulmonary disease.
od: Hynes, G, i dr.
Izdano: (2016)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
od: Pavord, I, i dr.
Izdano: (2017)

Chronic obstructive pulmonary disease – management of chronic disease
od: Ramakrishnan, S, i dr.
Izdano: (2020)

Chronic obstructive pulmonary disease: Management of chronic disease
od: Russell, R, i dr.
Izdano: (2012)

Chronic obstructive pulmonary disease: management of chronic disease
od: Bafadhel, M, i dr.
Izdano: (2016)

Chronic obstructive pulmonary disease: Management of chronic disease
od: Hambleton, K, i dr.
Izdano: (2016)

Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004.
od: Fabbri, L, i dr.
Izdano: (2005)

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.
od: Bafadhel, M, i dr.
Izdano: (2011)

Peptic ulceration, Helicobacter pylori seropositivity and chronic obstructive pulmonary disease.
od: Siva, R, i dr.
Izdano: (2013)

Nocturnal hypoxaemia in chronic obstructive pulmonary disease.
od: Stradling, JR, i dr.
Izdano: (1983)

Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease.
od: Ghebre, M, i dr.
Izdano: (2015)

Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease.
od: Barker, B, i dr.
Izdano: (2014)

Exacerbations of chronic obstructive pulmonary disease: Time to rename
od: Bafadhel, M, i dr.
Izdano: (2019)

Invasive to noninvasive ventilation in chronic obstructive pulmonary disease
od: Sharma, R, i dr.
Izdano: (2003)

Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design.
od: Gamble, E, i dr.
Izdano: (2006)

The importance of movement for people living with chronic obstructive pulmonary disease.
od: Williams, V, i dr.
Izdano: (2011)

Current controversies in chronic obstructive pulmonary disease. A report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee
od: Criner, GJ, i dr.
Izdano: (2019)

Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability.
od: Brightling, C, i dr.
Izdano: (2001)

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.
od: Brightling, C, i dr.
Izdano: (2005)

Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease.
od: Saha, S, i dr.
Izdano: (2008)

Towards eradication of chronic obstructive pulmonary disease: a Lancet Commission.
od: Dransfield, M, i dr.
Izdano: (2019)

Anxiety and panic in chronic obstructive pulmonary disease: The role of catastrophic thoughts
od: Gurney-Smith, B, i dr.
Izdano: (2002)

Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease.
od: Bafadhel, M, i dr.
Izdano: (2012)

Impaired mitochondrial microbicidal responses in chronic obstructive pulmonary disease macrophages
od: Bewley, M, i dr.
Izdano: (2017)

Indoor air quality in homes of patients with chronic obstructive pulmonary disease.
od: Osman, L, i dr.
Izdano: (2007)

Systolic blood pressure, chronic obstructive pulmonary disease and cardiovascular risk
od: Rao, S, i dr.
Izdano: (2023)

Use of the Oxford Participation and Activities Questionnaire in chronic obstructive pulmonary disease
od: Morley, D, i dr.
Izdano: (2019)

HOSPITAL AT HOME IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: IS IT A VIABLE OPTION?
od: Shepperd, S, i dr.
Izdano: (2012)

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
od: Gamble, E, i dr.
Izdano: (2003)

Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study.
od: Birring, S, i dr.
Izdano: (2002)

Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis
od: Pavord, I, i dr.
Izdano: (2016)

Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease.
od: Ramsey, S, i dr.
Izdano: (2006)

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
od: Brightling, C, i dr.
Izdano: (2000)

Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial
od: Santer, P, i dr.
Izdano: (2020)

Predictors of influenza PCR positivity in acute exacerbations of chronic obstructive pulmonary disease
od: Chen, Calvin You Jia, i dr.
Izdano: (2022)

Applying next-generation sequencing and multi-omics in chronic obstructive pulmonary disease
od: Tiew, Pei Yee, i dr.
Izdano: (2023)

Some chronic obstructive pulmonary disease will originate in neonatal intensive care units.
od: Bentham, JR, i dr.
Izdano: (2005)

Pre‐operative optimisation for chronic obstructive pulmonary disease: a narrative review
od: Lee, A, i dr.
Izdano: (2020)